Market Research Logo

Anxiety Disorders - Pipeline Review, H2 2016

Anxiety Disorders - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Anxiety Disorders - Pipeline Review, H2 2016’, provides an overview of the Anxiety Disorders pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anxiety Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anxiety Disorders and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Anxiety Disorders
    • The report reviews pipeline therapeutics for Anxiety Disorders by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Anxiety Disorders therapeutics and enlists all their major and minor projects
    • The report assesses Anxiety Disorders therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Anxiety Disorders
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Anxiety Disorders
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Anxiety Disorders pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Anxiety Disorders Overview
    Therapeutics Development
    Pipeline Products for Anxiety Disorders - Overview
    Pipeline Products for Anxiety Disorders - Comparative Analysis
    Anxiety Disorders - Therapeutics under Development by Companies
    Anxiety Disorders - Therapeutics under Investigation by Universities/Institutes
    Anxiety Disorders - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Unknown Stage Products
    Anxiety Disorders - Products under Development by Companies
    Anxiety Disorders - Products under Investigation by Universities/Institutes
    Anxiety Disorders - Companies Involved in Therapeutics Development
    AbbVie Inc
    Ache Laboratorios Farmaceuticos S/A
    Adamed Sp. z o.o.
    Addex Therapeutics Ltd
    Amorsa Therapeutics Inc.
    Avineuro Pharmaceuticals, Inc.
    Azevan Pharmaceuticals, Inc.
    Biohaven Pharmaceutical Holding Company Limited
    Bionomics Limited
    Boehringer Ingelheim GmbH
    C4X Discovery Holdings PLC
    Catalyst Pharmaceuticals, Inc.
    Corcept Therapeutics Incorporated
    Edgemont Pharmaceuticals, LLC
    Eisai Co., Ltd.
    Eli Lilly and Company
    Fabre-Kramer Pharmaceuticals, Inc.
    Gabather AB
    GlaxoSmithKline Plc
    GW Pharmaceuticals Plc
    Humanetics Corporation
    IntelGenx Corp.
    Intra-Cellular Therapies, Inc.
    INVENT Pharmaceuticals, Inc.
    Lead Discovery Center GmbH
    Marinus Pharmaceuticals, Inc.
    Merz Pharma GmbH & Co. KgaA
    Neuralstem, Inc.
    Neurelis, Inc.
    NeuroNascent, Inc.
    Newron Pharmaceuticals S.p.A.
    Nippon Chemiphar Co., Ltd.
    Omeros Corporation
    Otsuka Holdings Co., Ltd.
    Pherin Pharmaceuticals, Inc.
    Pragma Therapeutics
    Protagenic Therapeutics Inc.
    Suda Ltd
    Sumitomo Dainippon Pharma Co., Ltd.
    Synchroneuron Inc.
    Tonix Pharmaceuticals Holding Corp.
    Toray Industries, Inc.
    Trevena, Inc.
    TRImaran Pharma, Inc.
    Turing Pharmaceuticals AG
    Anxiety Disorders - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    18-MC - Drug Profile
    acamprosate calcium SR - Drug Profile
    ACH-36 - Drug Profile
    ADN-2013 - Drug Profile
    ADX-71441 - Drug Profile
    ADX-71743 - Drug Profile
    ADX-88178 - Drug Profile
    alprazolam - Drug Profile
    AM-3506 - Drug Profile
    AVN-0189 - Drug Profile
    AVN-101 - Drug Profile
    AVN-628 - Drug Profile
    BNC-210 - Drug Profile
    brexpiprazole - Drug Profile
    CPP-115 - Drug Profile
    D-473 - Drug Profile
    Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders - Drug Profile
    E-2508 - Drug Profile
    evenamide - Drug Profile
    FKW-00GA - Drug Profile
    fluvoxamine maleate - Drug Profile
    ganaxolone - Drug Profile
    gepirone hydrochloride ER - Drug Profile
    GT-001 - Drug Profile
    HL-9001 - Drug Profile
    HUF-101 - Drug Profile
    IC-87201 - Drug Profile
    INT-0036 - Drug Profile
    INV-107 - Drug Profile
    ITI-007 - Drug Profile
    KDAC-0001 - Drug Profile
    ketamine hydrochloride - Drug Profile
    lorazepam - Drug Profile
    lorazepam ER - Drug Profile
    LSN-2535717 - Drug Profile
    LY-2607540 - Drug Profile
    midazolam hydrochloride - Drug Profile
    modafinil - Drug Profile
    nabiximols - Drug Profile
    NC-2800 - Drug Profile
    NEO-1940 - Drug Profile
    NNI-351 - Drug Profile
    NSI-189 - Drug Profile
    OMS-527 - Drug Profile
    Peptide to Activate NPSR for Sleep Disorders and Anxiety Disorders - Drug Profile
    PGT-117 - Drug Profile
    PH-94B - Drug Profile
    PN-6047 - Drug Profile
    PT-00114 - Drug Profile
    remeglurant - Drug Profile
    riluzole - Drug Profile
    Rycal - Drug Profile
    S-107 - Drug Profile
    SCT-66 - Drug Profile
    Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile
    Small Molecule to Agonize CB1 Receptor for Inflammatory and Neuropathic Pain - Drug Profile
    Small Molecule to Antagonize CRF-1 Receptor for Anxiety Disorders - Drug Profile
    Small Molecule to Antagonize GPR31 for Anxiety Disorders - Drug Profile
    Small Molecule to Inhibit FKBP51 for Anxiety and Major Depressive Disorder - Drug Profile
    Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis - Drug Profile
    Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile
    Small Molecule to Target Oxytocin for Autism and Anxiety Disorders - Drug Profile
    Small Molecules for Autism Spectrum Disorders and Obsessive Compulsive Disorders - Drug Profile
    Small Molecules to Activate Sigma Receptor for Panic and Schizoaffective Disorders - Drug Profile
    Small Molecules to Activate Translocator Protein for Anxiety - Drug Profile
    Small Molecules to Antagonize CRHR1 for Depression and Anxiety Disorders - Drug Profile
    Small Molecules to Antagonize GABAA1 for Alcohol Addiction and Anxiety - Drug Profile
    Small Molecules to Antagonize Glucocorticoid Receptor II for Post Traumatic Stress Disorder - Drug Profile
    Small Molecules to Antagonize mGlu2 for Anxiety and Depression - Drug Profile
    Small Molecules to Antagonize mGluR3 for Anxiety and Depression - Drug Profile
    Small Molecules to Antagonize mGluR5 for Anxiety - Drug Profile
    Small Molecules to Antagonize mGluR7 for Central Nervous System Disorders - Drug Profile
    Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile
    Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile
    Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy - Drug Profile
    Small Molecules to Modulate Mineralocorticoid Receptor for Anxiety Disorders and Depression - Drug Profile
    Small Molecules to Target Nicotinic Acetylcholine Receptors for Anxiety Disorder - Drug Profile
    Small Molecules to Target NMDA Receptor for Obsessive-Compulsive Disorder - Drug Profile
    Small Molecules to Target NMDA Receptor for Post-Traumatic Stress Disorder - Drug Profile
    SRX-246 - Drug Profile
    SRX-251 - Drug Profile
    STX - Drug Profile
    Synthetic Peptide to Antagonize EPHA4 for Post-Traumatic Stress Disorder - Drug Profile
    TGFK-08AA - Drug Profile
    TGSC-01AA(4) - Drug Profile
    TNX-102 - Drug Profile
    TRV-250 - Drug Profile
    UCM-765 - Drug Profile
    Vaccine for CNS Disorders - Drug Profile
    VAD-1 - Drug Profile
    VAD-2 - Drug Profile
    VU-0431316 - Drug Profile
    VU-0456810 - Drug Profile
    ZL-006 - Drug Profile
    Anxiety Disorders - Dormant Projects
    Anxiety Disorders - Discontinued Products
    Anxiety Disorders - Product Development Milestones
    Featured News & Press Releases
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Anxiety Disorders, H2 2016
    Number of Products under Development for Anxiety Disorders - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Development by Companies, H2 2016 (Contd..1)
    Number of Products under Development by Companies, H2 2016 (Contd..2)
    Number of Products under Development by Companies, H2 2016 (Contd..3)
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Comparative Analysis by Unknown Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016 (Contd..1)
    Products under Development by Companies, H2 2016 (Contd..2)
    Products under Development by Companies, H2 2016 (Contd..3)
    Products under Development by Companies, H2 2016 (Contd..4)
    Products under Development by Companies, H2 2016 (Contd..5)
    Products under Investigation by Universities/Institutes, H2 2016
    Anxiety Disorders - Pipeline by AbbVie Inc, H2 2016
    Anxiety Disorders - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016
    Anxiety Disorders - Pipeline by Adamed Sp. z o.o., H2 2016
    Anxiety Disorders - Pipeline by Addex Therapeutics Ltd, H2 2016
    Anxiety Disorders - Pipeline by Amorsa Therapeutics Inc., H2 2016
    Anxiety Disorders - Pipeline by Avineuro Pharmaceuticals, Inc., H2 2016
    Anxiety Disorders - Pipeline by Azevan Pharmaceuticals, Inc., H2 2016
    Anxiety Disorders - Pipeline by Biohaven Pharmaceutical Holding Company Limited, H2 2016
    Anxiety Disorders - Pipeline by Bionomics Limited, H2 2016
    Anxiety Disorders - Pipeline by Boehringer Ingelheim GmbH, H2 2016
    Anxiety Disorders - Pipeline by C4X Discovery Holdings PLC, H2 2016
    Anxiety Disorders - Pipeline by Catalyst Pharmaceuticals, Inc., H2 2016
    Anxiety Disorders - Pipeline by Corcept Therapeutics Incorporated, H2 2016
    Anxiety Disorders - Pipeline by Edgemont Pharmaceuticals, LLC, H2 2016
    Anxiety Disorders - Pipeline by Eisai Co., Ltd., H2 2016
    Anxiety Disorders - Pipeline by Eli Lilly and Company, H2 2016
    Anxiety Disorders - Pipeline by Fabre-Kramer Pharmaceuticals, Inc., H2 2016
    Anxiety Disorders - Pipeline by Gabather AB, H2 2016
    Anxiety Disorders - Pipeline by GlaxoSmithKline Plc, H2 2016
    Anxiety Disorders - Pipeline by GW Pharmaceuticals Plc, H2 2016
    Anxiety Disorders - Pipeline by Humanetics Corporation, H2 2016
    Anxiety Disorders - Pipeline by IntelGenx Corp., H2 2016
    Anxiety Disorders - Pipeline by Intra-Cellular Therapies, Inc., H2 2016
    Anxiety Disorders - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016
    Anxiety Disorders - Pipeline by Lead Discovery Center GmbH, H2 2016
    Anxiety Disorders - Pipeline by Marinus Pharmaceuticals, Inc., H2 2016
    Anxiety Disorders - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2016
    Anxiety Disorders - Pipeline by Neuralstem, Inc., H2 2016
    Anxiety Disorders - Pipeline by Neurelis, Inc., H2 2016
    Anxiety Disorders - Pipeline by NeuroNascent, Inc., H2 2016
    Anxiety Disorders - Pipeline by Newron Pharmaceuticals S.p.A., H2 2016
    Anxiety Disorders - Pipeline by Nippon Chemiphar Co., Ltd., H2 2016
    Anxiety Disorders - Pipeline by Omeros Corporation, H2 2016
    Anxiety Disorders - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
    Anxiety Disorders - Pipeline by Pherin Pharmaceuticals, Inc., H2 2016
    Anxiety Disorders - Pipeline by Pragma Therapeutics, H2 2016
    Anxiety Disorders - Pipeline by Protagenic Therapeutics Inc., H2 2016
    Anxiety Disorders - Pipeline by Suda Ltd, H2 2016
    Anxiety Disorders - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
    Anxiety Disorders - Pipeline by Synchroneuron Inc., H2 2016
    Anxiety Disorders - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2016
    Anxiety Disorders - Pipeline by Toray Industries, Inc., H2 2016
    Anxiety Disorders - Pipeline by Trevena, Inc., H2 2016
    Anxiety Disorders - Pipeline by TRImaran Pharma, Inc., H2 2016
    Anxiety Disorders - Pipeline by Turing Pharmaceuticals AG , H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Anxiety Disorders - Dormant Projects, H2 2016
    Anxiety Disorders - Dormant Projects (Contd..1), H2 2016
    Anxiety Disorders - Dormant Projects (Contd..2), H2 2016
    Anxiety Disorders - Dormant Projects (Contd..3), H2 2016
    Anxiety Disorders - Dormant Projects (Contd..4), H2 2016
    Anxiety Disorders - Dormant Projects (Contd..5), H2 2016
    Anxiety Disorders - Dormant Projects (Contd..6), H2 2016
    Anxiety Disorders - Dormant Projects (Contd..7), H2 2016
    Anxiety Disorders - Dormant Projects (Contd..8), H2 2016
    Anxiety Disorders - Dormant Projects (Contd..9), H2 2016
    Anxiety Disorders - Dormant Projects (Contd..10), H2 2016
    Anxiety Disorders - Dormant Projects (Contd..11), H2 2016
    Anxiety Disorders - Dormant Projects (Contd..12), H2 2016
    Anxiety Disorders - Dormant Projects (Contd..13), H2 2016
    Anxiety Disorders - Dormant Projects (Contd..14), H2 2016
    Anxiety Disorders - Discontinued Products, H2 2016
    Anxiety Disorders - Discontinued Products (Contd..1), H2 2016
    Anxiety Disorders - Discontinued Products (Contd..2), H2 2016
    Anxiety Disorders - Discontinued Products (Contd..3), H2 2016
    Anxiety Disorders - Discontinued Products (Contd..4), H2 2016
    List of Figures
    Number of Products under Development for Anxiety Disorders, H2 2016
    Number of Products under Development for Anxiety Disorders - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report